A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our Strategy Our business strategy is to in-license or otherwise acquire the rights to intellectual property and know how that enables us to develop and bring to market differentiated evidence-based solutions that we believe can address unmet needs in women’s health and enhance outcomes and convenience, and that represent compelling and meaningful market opportunities. Certain assets we have in-licensed have existing clinical proof-of-concept data or an established safety profile for the active pharmaceutical ingredient that we seek to leverage. We may pursue regulatory approval of a product candidate through clinical development or, if the active pharmaceutical ingredient is on the FDA’s list of bulk drug substances for which there is a clinical need, we may seek to bring it to market under Section 503B of the FDCA. In certain circumstances, as discussed in more detail below with respect to our proprietary Sildenafil Cream formulation, we may pursue both pathways.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2016 |
|---|---|---|---|---|---|---|
| Revenue | -57K | - | - | - | 0 | - |
| Net Income | -17M | -4.1M | -30M | -31M | -39M | -39M |
| EPS | $-1.83 | $-0.48 | $-49.80 | $-4.44 | $-7.56 | $-97.20 |
| Free Cash Flow | -6.8M | 4.8M | -39M | -18M | -29M | -34M |
| ROIC | -44.9% | -106.1% | -145.4% | -56.6% | -99.8% | -100.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.01 | -0.22 | -0.28 | 0.04 | 0.01 | 0.70 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -17M | -23M | -31M | -31M | -39M | -37M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -611.1% | - | - | -278.5% | -99.8% | -127.1% |
| Shares Outstanding | 14M | 8M | 1M | 7M | 5M | 0M |
Dare Bioscience, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Dare Bioscience, Inc. (DARE) has a 5-year average return on invested capital (ROIC) of -101.7%. This is below average and may indicate limited pricing power.
Dare Bioscience, Inc. (DARE) has a market capitalization of $25M. It is classified as a small-cap stock.
Dare Bioscience, Inc. (DARE) does not currently pay a regular dividend.
Dare Bioscience, Inc. (DARE) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Dare Bioscience, Inc. (DARE) generated $5 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Dare Bioscience, Inc. (DARE) reported earnings per share (EPS) of $-0.48 in its most recent fiscal year.
The Ledger Terminal provides 9 years of financial data for Dare Bioscience, Inc. (DARE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Dare Bioscience, Inc. (DARE) has a book value per share of $-0.71, based on its most recent annual SEC filing.
No recent press releases.